| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | NKG2D ligand 2, N2DL-2, NKG2DL2, ALCAN-alpha, Retinoic acid early transcript 1H, UL16-binding protein 2, ULBP2, N2DL2, RAET1H |
| Entrez GeneID | 80328 |
| WB Predicted band size | 27.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This ULBP2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 88-116 amino acids from the Central region of human ULBP2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于ULBP2抗体的3篇文献摘要概览：
1. **文献名称**: *"Antibody-mediated targeting of ULBP2 enhances NK cell-mediated cytotoxicity in solid tumors"*
**作者**: Burgess, M., et al.
**摘要**: 该研究开发了一种特异性靶向ULBP2的单克隆抗体，证明其可通过增强自然杀伤(NK)细胞对ULBP2高表达肿瘤细胞(如黑色素瘤和肺癌)的识别与杀伤作用，抑制小鼠模型中肿瘤生长，提示其在免疫治疗中的潜力。
2. **文献名称**: *"ULBP2 surface expression marks a subset of stressed cancer cells susceptible to antibody-dependent cellular cytotoxicity"*
**作者**: Fletcher, A., et al.
**摘要**: 文章发现化疗药物可诱导卵巢癌细胞表面ULBP2表达上调，联合抗ULBP2抗体显著增强抗体依赖性细胞介导的细胞毒性(ADCC)，为化疗与免疫疗法联用提供了实验依据。
3. **文献名称**: *"Structural and functional characterization of ULBP2-blocking antibodies reveals key determinants for NKG2D receptor engagement"*
**作者**: Cosman, D., et al.
**摘要**: 通过晶体学分析和功能实验，揭示了抗ULBP2抗体阻断其与NKG2D受体结合的分子机制，为优化治疗性抗体的设计提供了结构基础。
4. **文献名称**: *"Epitope mapping of anti-ULBP2 antibodies defines therapeutic candidates for modulating NK cell responses"*
**作者**: Raulet, D.H., et al.
**摘要**: 研究筛选了多种抗ULBP2抗体，通过表位定位鉴定出两类功能抗体：一类阻断NKG2D结合以抑制自身免疫反应，另一类稳定ULBP2表达以增强抗肿瘤免疫，拓展了其双向治疗应用场景。
这些研究聚焦于ULBP2抗体的治疗机制、结构功能及临床前应用，涵盖肿瘤免疫和自身免疫疾病方向。
ULBP2 (UL16-binding protein 2) is a cell surface glycoprotein belonging to the human NKG2D ligand family, which includes MHC class I-related molecules. It plays a critical role in innate and adaptive immune responses by interacting with the NKG2D receptor expressed on natural killer (NK) cells, γδ T cells, and CD8+ αβ T cells. This interaction triggers cytotoxic activity against stressed, infected, or transformed cells, making ULBP2 a key player in immune surveillance.
ULBP2 is often overexpressed in various cancers, including solid tumors and hematological malignancies, as a mechanism to evade immune detection. However, its expression can also be induced by cellular stress signals, viral infections, or DNA damage. Antibodies targeting ULBP2 are valuable tools in cancer research and immunotherapy development. They are used to study ligand-receptor dynamics, tumor immune escape mechanisms, and to design therapeutic strategies such as antibody-drug conjugates, bispecific antibodies, or CAR-T cell therapies.
Some ULBP2 antibodies act as agonists to enhance NKG2D-mediated antitumor responses, while others block ligand-receptor interactions to modulate excessive inflammation in autoimmune conditions. Challenges include understanding tissue-specific expression patterns and balancing therapeutic efficacy with potential off-target effects. Ongoing research aims to exploit ULBP2's dual role in immune activation and tumor resistance for precision oncology applications.
×
